Revisiting the PD-1 pathway is a research paper published in Science Advances (2020). On theSindex it has a DataRank of 0. It has been cited 529 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CA238263
National Institutes of Health
Grant: CA212605
National Institutes of Health
Grant: CA229784
National Institutes of Health
Grant: AR073494
NCI NIH HHS
Grant: R01 CA212605
NCI NIH HHS
Grant: R01 CA229784
NCI NIH HHS
Grant: R01 CA238263
NIAMS NIH HHS
Grant: R21 AR073494
National Institutes of Health
Grant: 1R21AR073494-01A1
Exploitation of PD1-mediated tolerogenic signals for the treatment of SLE
National Institutes of Health
Grant: 5R01CA238263-03
The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
National Institutes of Health
Grant: 1R01CA212605-01A1
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
National Institutes of Health
Grant: 5R01CA229784-04
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
Additional file 1 of Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
Additional file 1 of Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
Additional file 1 of Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
Additional file 1 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 1 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 1 of PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Additional file 1 of PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Additional file 2 of PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Additional file 2 of PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Additional file 3 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 3 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 4 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 2 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 4 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 2 of Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Additional file 1 of A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Additional file 1 of A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity